Tohoku University. Research Profiles


Clinical application of sustained-release device



We have developed a device that allows long-term sustained release of drugs regardless of their molecular weight. The initial purpose of the development was to target intractable retinal diseases. Since it is a subconjunctival (superscleral) operation, it is highly safe and can be removed immediately if a problem occurs. Currently, a doctor-initiated clinical trial is being conducted for patients with retinitis pigmentosa. There is an advantage that it can be used for various retinal diseases and eye diseases as long as there is an appropriate drug. Although the patent is open to the public, we believe that it can be applied to other than retinal diseases.

Targeted Application(s)/Industry

Due to the possibility of sustained release of various drugs and aptamers, it may be applicable to diseases in which topical drug administration is considered. Joint research with related parties is possible.


Division of Clinical Cell Therapy, Graduate School of Medicine

ABE Toshiaki , Professor


Related Information

Protective Effects of Sustained Unoprostone Release Device in Rhodopsin Pro347Leu Transgenic Rabbits. Investigative Ophthalmology & Visual Science, 57 (12), 4017 (2016). Nagai, N et al.
A platform for controlled dual-drug delivery to the retina: rotective effects against light-induced retinal damage in rats. Advanced Healthcare Materials, 3(10), 1555-1560 (2014) Nagai N et al.